Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04286958
- Locations
- 🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-08-14
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04233294
- Locations
- 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 30
- Registration Number
- NCT04231552
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Guangzhou Institute of Respiratory Disease
- Target Recruit Count
- 56
- Registration Number
- NCT04225364
- Locations
- 🇨🇳
Jingpei Li, Guangzhou, Guangdong, China
Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 52
- Registration Number
- NCT04221516
- Locations
- 🇨🇳
Southern medical university, Guangzhou, Guangdong, China
Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-12-26
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 45
- Registration Number
- NCT04211090
- Locations
- 🇨🇳
Li-Kun Chen, Guangzhou, Guangzhou, China
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 580
- Registration Number
- NCT04208347
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
🇨🇳Lanzhou University Second Hospital, Lanzhou, China
🇨🇳Affiliated Hospital of Hebei University, Baoding, China
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Zhongshan Hospital Xiamen University
- Target Recruit Count
- 23
- Registration Number
- NCT04202978
- Locations
- 🇨🇳
Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Fujian Medical University
- Target Recruit Count
- 53
- Registration Number
- NCT04195828
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04174339
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.